Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00027027
Status:
COMPLETED
Last Update Posted:
2015-07-27
First Post:
2001-11-15
Brief Title:
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase I Open-Label Multicenter Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 rhuMAb 2C4 Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Phase I study is to test the safety of rhuMAb 2C4 to see what effects good and bad it has on patients with certain types of cancer and also to find the highest dose of rhuMAb that can be given without causing severe side effects All study participants will be assigned to specific group to evaluate different dosages of rhuMAb 2C4 The study is scheduled to run for up to one year depending on how patients respond to the study treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None